Head, Neck and Thyroid Cancer: Chemoradiation, EGFR and Radioiodine
Two cancers share a neighbourhood in the neck but almost nothing else. One is a squamous cancer driven by smoke, alcohol or a virus, fought with radiation, cisplatin and antibodies. The other is a gland so hungry for iodine that we feed it a radioactive form and let it poison itself from within — a targeted therapy invented before the phrase existed. Learn to tell them apart and the whole management falls into place.
Picture the thyroid's elegant Achilles' heel. To make its hormone, the gland must trap iodine from the blood — greedily, more than any other tissue in the body. A well-differentiated thyroid cancer usually keeps that same hunger. So we do something almost poetic: we hand the patient a capsule of RADIOACTIVE iodine (iodine-131). The cancer cells, unable to tell the difference, soak it up — and the radiation packed inside irradiates them from the inside out, while the rest of the body, indifferent to iodine, is largely spared. A therapy that finds its own target, discovered decades before we had a word for 'targeted therapy'.
Two regions, two entirely different diseases
Geography misleads here. Head and neck cancer and thyroid cancer sit inches apart, yet their biology, treatment and prognosis diverge almost completely. Head and neck squamous cell carcinoma (HNSCC) arises from the lining of the mouth, throat and larynx — a tissue battered by carcinogens. Thyroid cancer arises from a hormone-making gland with a unique metabolic quirk we can exploit. Treat them as one and you will misjudge both; this chapter keeps them side by side precisely so the contrast teaches the drugs.
Head and neck squamous cell carcinoma: smoke, alcohol and a virus
Classically, HNSCC is a cancer of tobacco and alcohol, whose effects multiply when combined. But a second, distinct pathway now drives many throat (oropharyngeal) cancers: the human papillomavirus (HPV), the same virus behind cervical cancer. This matters enormously, because HPV-positive throat cancers behave differently — they respond better and carry a markedly BETTER prognosis than HPV-negative, tobacco-driven tumours. Determining HPV status (often via a p16 stain) is now a standard, non-negotiable step in an oropharyngeal cancer work-up.
HPV status is not a footnote — it changes the conversation. HPV-positive oropharyngeal cancer, typically in a younger non-smoker, is so much more curable that it is now staged separately, and clinical trials are actively testing whether treatment can be DE-ESCALATED (less radiation, less chemo) to spare these curable patients the long-term toxicity. Forgetting to ask 'is this HPV-driven?' misjudges both prognosis and intensity.
For locally advanced disease, the backbone is chemoradiation. When HNSCC is locally advanced but has not spread distantly, the aim is cure with organ preservation — treating the tumour without cutting out the voice box or tongue. The standard is concurrent chemoradiation: radiotherapy given together with CISPLATIN, a platinum chemotherapy that acts as a radiosensitizer, making the radiation dramatically more lethal to the tumour. For patients who cannot tolerate cisplatin, the anti-EGFR antibody CETUXIMAB given with radiotherapy is an established alternative — a targeted drug rather than a classical cytotoxic.
Cetuximab blocks the epidermal growth factor receptor (EGFR), a signal HNSCC cells lean on to grow. It is a monoclonal antibody — the same class covered in depth in the Monoclonal antibodies chapter — so it ends in '-mab' and works from outside the cell. For recurrent or metastatic disease, the field has moved on: immune checkpoint inhibitors (pembrolizumab, nivolumab) — the anti-PD-1 antibodies detailed in the Checkpoint inhibitors chapter — are now first-line, given alone or added to chemotherapy, releasing the immune brakes so the body's own T cells attack the tumour.
- HNSCC arises from the mucosal lining of mouth, throat and larynx.
- Two drivers: tobacco/alcohol, and HPV (HPV-positive = better prognosis).
- Locally advanced → concurrent chemoradiation with cisplatin (a radiosensitizer).
- Cetuximab (anti-EGFR) + radiotherapy is the alternative when cisplatin is unsuitable.
- Recurrent/metastatic → checkpoint immunotherapy (pembrolizumab, nivolumab) ± chemo.
Thyroid cancer: usually gentle, occasionally not
Most thyroid cancers are DIFFERENTIATED — the papillary and follicular types — meaning the cells still resemble and behave much like normal thyroid tissue. This is wonderful news: differentiated thyroid cancer carries an EXCELLENT prognosis, with most patients cured. The core treatment is surgery (removing the gland), followed in selected patients by radioactive iodine (I-131) to ablate any remaining thyroid or cancer cells, plus lifelong levothyroxine. That levothyroxine does double duty: it replaces the hormone the removed gland no longer makes, AND it is dosed to SUPPRESS thyroid-stimulating hormone (TSH), the very signal that would otherwise urge any residual cancer cells to grow.
The logic of radioactive iodine and TSH-suppressive levothyroxine belongs to endocrine physiology — the iodine uptake mechanism, the hypothalamic–pituitary–thyroid axis and levothyroxine dosing are all covered in the Endocrine thyroid section. Here the point is oncological: the tumour's retained iodine hunger is what makes I-131 work, and keeping TSH low removes the growth signal. Two elegant uses of one gland's own physiology, turned against its cancer.
When the differentiated cancer stops taking up iodine, the plan changes. A minority of differentiated thyroid cancers lose their iodine-avidity and become radioiodine-refractory — the elegant trick no longer works. And two other thyroid cancers never played by these rules: medullary thyroid cancer (from calcitonin-producing C cells, not iodine-handling cells) and anaplastic thyroid cancer (an undifferentiated, aggressive tumour with a grim prognosis). For all of these, we turn to targeted oral drugs — the MULTIKINASE INHIBITORS lenvatinib and sorafenib, which block the tyrosine kinase signals (including tumour blood-vessel growth) that these cancers depend on.
Modern thyroid oncology is increasingly mutation-driven, and these agents sit in the Kinase inhibitors chapter. For RET-altered thyroid cancers (common in medullary disease), the selective RET inhibitor selpercatinib is strikingly effective. For the rare BRAF-mutant anaplastic thyroid cancer, the combination dabrafenib plus trametinib (a BRAF inhibitor with a MEK inhibitor) can produce meaningful responses in a disease that was once almost untreatable. The lesson: test for the driver mutation, then pick the key that fits its lock.
- Most thyroid cancer is differentiated (papillary/follicular) with an excellent prognosis.
- Core plan: surgery → radioactive iodine (I-131) ablation → TSH-suppressive levothyroxine.
- I-131 works because the cancer keeps the thyroid's natural iodine hunger.
- Radioiodine-refractory disease → multikinase inhibitors (lenvatinib, sorafenib).
- Match the mutation: RET-altered → selpercatinib; BRAF-mutant anaplastic → dabrafenib + trametinib.
- Medullary and anaplastic cancers do NOT respond to radioiodine — they need targeted agents.
- Forgetting to check HPV status in oropharyngeal cancer — it changes prognosis and opens the door to treatment de-escalation.
- Starting cisplatin-based chemoradiation without checking renal function and hearing — cisplatin is nephrotoxic and ototoxic.
- Assuming all thyroid cancers behave alike — differentiated is radioiodine-sensitive with a great prognosis, while anaplastic and medullary need targeted drugs.
- Treating levothyroxine after thyroid cancer as simple replacement — it is dosed to actively suppress TSH, not just normalize it.
Radioactive iodine (I-131) is an effective treatment for differentiated thyroid cancer mainly because:
- HNSCC is smoke/alcohol- or HPV-driven; always determine HPV status (HPV-positive = better prognosis).
- Locally advanced HNSCC → cisplatin chemoradiation; cetuximab (anti-EGFR) is the alternative; recurrent/metastatic → checkpoint immunotherapy.
- Differentiated thyroid cancer: excellent prognosis — surgery, I-131 ablation, TSH-suppressive levothyroxine.
- Radioiodine-refractory, medullary or anaplastic disease → targeted kinase inhibitors (lenvatinib/sorafenib; selpercatinib for RET; dabrafenib+trametinib for BRAF-mutant anaplastic).
- NCCN Clinical Practice Guidelines in Oncology — Head and Neck Cancers.
- NCCN Clinical Practice Guidelines in Oncology — Thyroid Carcinoma.
- ESMO Clinical Practice Guidelines — Squamous cell carcinoma of the head and neck: diagnosis, treatment and follow-up.
- ESMO Clinical Practice Guidelines — Thyroid cancer (differentiated, medullary and anaplastic).
- American Thyroid Association (ATA) Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer.
- DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology — Head and neck & endocrine cancers.
